NVAX Jul 2024 15.500 call
| Previous Close | 0.1200 |
| Open | 0.0900 |
| Bid | 0.0700 |
| Ask | 0.1000 |
| Strike | 15.50 |
| Expire Date | 2024-07-05 |
| Day's Range | 0.0900 - 0.0900 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 167 |
GuruFocus.comInsider Sale: Director James Young Sells Shares of Novavax Inc (NVAX)
The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 61,760 shares of Novavax Inc. Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.
ZacksNovavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe
Novavax (NVAX) seeks marketing authorization in the European Union for an updated version of its COVID-19 vaccine, which has been formulated to target the JN.1 variant.
PR NewswireNovavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has filed for a type II variation of existing Marketing Authorization with the European Medicines Agency (EMA) for its JN.1 COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older. The submission is in line with guidance from EMA and the World Health Organization to target the JN.1 lineage this fall.1,2
